The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) ...

A high proportion of patients with moderate to severe plaque psoriasis achieved long-term on-treatment remission for 3 years with bimekizumab, according to a poster presentation at Winter Clinical ...

When you have psoriasis — a skin disease that typically causes thick, itchy, scaly, or discolored patches of skin — finding a treatment that works for you can be a challenge. Luckily, there are more ...

Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...

Creams play an important role in the treatment of plaque psoriasis to help improve the appearance of the skin and reduce itching. New medicines that target the underlying inflammation caused by plaque ...

Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas home phototherapy offered lower costs for patients and payers, according to a ...

For people with chronic skin conditions, telehealth altered how they care for their skin and their bodies by removing ...

In a recent review published in Signal Transduction and Targeted Therapy, researchers reviewed existing data on psoriasis etiopathogenesis and treatment. Psoriasis is a prevalent, chronic, ...

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study. A recent poster ...

"I was very ashamed. I felt like everywhere people were judging me," Amber Dean tells PEOPLE, recalling when her symptoms ...